Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026

Phase 3amlenetugPositive

AI Analysis

Summary

Lundbeck announced it will present Phase III data on amlenetug for multiple system atrophy at the MDS 2026 conference, including late-breaking MASCOT oral presentation characterizing the clinical profile and participant diversity in the ongoing global trial.

Clinical Trial Data

Phase

Phase III

Outcome Details

Late-breaking Phase III MASCOT oral presentation characterizing clinical profile and diversity of participants in ongoing global Phase III trial

Importance:6/10

Sentiment:

0.30

movement disordersmultiple system atrophyParkinson's diseasePhase IIIMDS 2026 conferenceclinical trial data

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Biotech on October 2, 2026 6:29 AM

Read Original